IGC Pharma Price Target Lifted to $5.25 on Phase 2 CALMA Data
Ascendiant Capital Markets lifted IGC Pharma's price target to $5.25 per share, citing positive Phase 2 CALMA trial progress on IGC-AD1 and strong catalysts expected throughout 2026. The firm highlighted anticipated clinical readouts and AI-driven pipeline advances, including TGR-63 targeting amyloid plaques and early-stage neurodegeneration programs.
1. Price Target Raised to $5.25
Ascendiant Capital Markets increased IGC Pharma's price target to $5.25 per share, citing positive interim results from the ongoing Phase 2 CALMA trial of IGC-AD1 and anticipated catalysts throughout 2026 that could validate the therapy's efficacy.
2. Ongoing Phase 2 Trial and Expected Catalysts
The CALMA trial is evaluating IGC-AD1 for agitation in Alzheimer's dementia, with key readouts and enrollment milestones projected in mid-2026 that could drive the stock. Additional catalysts include clinical updates on TGR-63 amyloid plaque targeting and early neurodegeneration programs.
3. Broader Pipeline and AI Integration
IGC Pharma leverages AI to accelerate drug discovery and optimize clinical trials across its pipeline, which includes TGR-63, tau aggregation inhibitors, neurodegeneration candidates and metabolic disorder assets, enhancing long-term growth prospects beyond the CALMA study.